JNJ-67571244

N/A

Report date: 2026/03/19 17:15:04

Base Information

Drug NameJNJ-67571244

Drug Alias NameJNJ-1244JNJ-67571244JNJ-67371244

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsT cell surface glycoprotein CD3 inhibitors

TargetsT cell surface glycoprotein CD3Myeloid cell surface antigen CD33

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermanySpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A